This inventor holds 1 USPTO granted patent. Top assignee: University of Cambridge. Active years: 2009.
Company Filing History:
Years Active: 2009
Title: Lorna McLeod Williamson: Innovator in Binding Molecules
Introduction
Lorna McLeod Williamson is a distinguished inventor based in Cambridge, GB. She has made significant contributions to the field of biotechnology, particularly in the development of binding molecules derived from immunoglobulins. Her innovative work focuses on creating molecules that can bind target substances without triggering adverse immune responses.
Latest Patents
Lorna McLeod Williamson holds a patent for "Binding molecules derived from immunoglobulins which do not trigger complement mediated lysis." This patent discloses recombinant polypeptides that contain a binding domain capable of binding a target molecule and an effector domain with an amino acid sequence substantially homologous to a constant domain of a human immunoglobulin heavy chain. The binding molecules are characterized by their ability to bind target molecules without causing significant complement-dependent lysis or cell-mediated destruction. The patent also discusses the modification of specific regions to render the molecule null allotypic, along with the disclosure of nucleic acids, host cells, production processes, and pharmaceutical preparations.
Career Highlights
Lorna McLeod Williamson is affiliated with the University of Cambridge, where she continues her research and development in the field of immunology and biotechnology. Her work has garnered attention for its potential applications in therapeutic settings, particularly in the design of safer and more effective binding molecules.
Collaborations
Lorna has collaborated with notable colleagues, including Kathryn Lesley Armour and Michael Ronald Clark, contributing to advancements in their shared field of research.
Conclusion
Lorna McLeod Williamson's innovative work in binding molecules represents a significant advancement in biotechnology. Her contributions have the potential to impact various therapeutic applications, showcasing the importance of her research in the scientific community.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
